Country Reports

With a fresh, business-minded administration in place, economic growth, a burgeoning middle class, and a greater openness towards cooperation between the public and private sectors, the fundamentals are there for Ecuador’s life sciences industry to shine. Medicine sales per capita are extremely high for Latin America and the dollarization of the economy is helping soothe…

With GDP growth at 4.6% for 2017, pharma market growth of 4.2%, 38 million people, and a strategic location in the center of Europe, Poland has solid foundations for success in healthcare and the life sciences. The situation is improving for both generics companies and innovators and there are plans to increase public health expenditure…

While Lithuania, Latvia and Estonia have a lot in common – small, high-income economies and Eurozone members situated on the Eastern coast of the Baltic Sea – it would be inadvisable to consider the Baltic states as one homogenous block.   This report explores the peculiarities of the healthcare and life science industries of these…

India can claim with some degree of force to be ‘the pharmacy to the world.’ Not only are Indian medicines consumed in the US and EU, but enterprising Indian companies are increasingly looking towards huge underserved developing markets across the globe.   Furthermore, Indian companies are moving into the field of biologics; a handful of…

Despite a tiny domestic market size, the Lithuanian life sciences sector is full of hidden surprises. Comprising four percent of the nation’s entire GDP, with one percent accounted for by a burgeoning biotechnology sector, Lithuania can draw on a strong science R&D infrastructure and a talented domestic labor pool.   The multinational affiliate leaders, heads…

With an exit from a period of recession in 2017, a new era of change and positivity is underway in Brazil. Stakeholders from across the public and private sectors are pulling together through strategic partnerships and dialogues to increase both the quantity and quality of the healthcare provided to the 160 million Brazilians who rely…

This report offers companies, investors, policymakers, and stakeholders crucial insight into Switzerland; a country  located at the heart of Europe, home to some of the world’s most important international health institutions as well as two of its largest pharmaceutical companies in Novartis and Roche, and with a number one ranking globally in terms of ease…

With economic prosperity, political stability and significant growth prospects, Canada has much to admire. However, Canadians still lack universal drug coverage and Canadian health innovation has lagged behind that of the world leaders in this area.   This report explores how these discrepancies are being remedied; including state R&D investment initiatives, increased inter-stakeholder dialogue, and…

With an admirable legacy of excellence behind it, Austria’s healthcare and life science industry is poised to take the next step and help make the country a genuine hub for both its region and for Europe.   Vienna is already fast establishing itself as Central Europe’s innovation hub as well as recently being ranked as…

Squirreled away right on the South-Eastern fringe of Europe, Bulgaria still has a tendency to be overlooked and underestimated by the uninitiated. Not so by the international pharmaceuticals industry, however, which has long considered what is one of the EU’s most recent member states to be a comparatively uncomplicated and hospitable place for doing business;…